Document is current
Any future updates will be listed below
-
Authors
Adil, Asif https://orcid.org/0000-0002-5415-6516
Xiang, Jingyu
Piccirillo, Nicola
Harris, Hillary G.
Sica, Simona https://orcid.org/0000-0003-2426-3465
DiPersio, John F. https://orcid.org/0000-0002-0429-3133
Hurwitz, Stephanie N. https://orcid.org/0000-0002-6975-9168
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1K08HL175130-01)
- License Information
-
More Information
Article History
Received: 28 August 2025
Revised: 26 January 2026
Accepted: 24 February 2026
First Online: 17 March 2026
Competing interests
: John F. DiPersio: Consulting/Advisory Committees Rivervest, Bioline, Incyte, NeoImmuneTech, Vertex, Bluebird Bio. Employment/salary: Washington University. Ownership Investment: Magenta, Wugen. All other authors declare no financial or non-financial competing interests.
